Optimi Health, a Canada-based pharmaceuticals maker specializing in MDMA and psilocybin, announced terms for its IPO on Friday.
The Princeton, Canada-based company plans to raise $15 million by offering 2.1 million shares at a price range of $6 to $8.
Because Optimi Health will have a post-IPO market capitalization of less than $50 million, it will be excluded from Renaissance Capital's 2026 IPO stats.
The company is a licensed Canadian drug manufacturer that produces controlled substances like MDMA and psilocybin. It operates two facilities in British Columbia and holds multiple licenses that allow it to manufacture, import, and distribute these substances within legal limits. Its approvals cover everything from producing active ingredients from plants to handling and supplying psychedelics in regulated quantities.
Optimi Health was founded in 2020 and booked plans to list on the Nasdaq under the symbol OPTH. Joseph Gunnar is the sole bookrunner on the deal.
